A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee.

Trial Profile

A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 07 Sep 2017 According to a Flexion Therapeutics media release, post-hoc pooled analysis of this and two other trials (see CT profiles 243924 and 234469) will be presented at PAINWeek 2017.
    • 24 May 2017 Results assessing cost-effectiveness of Extended-Release Triamcinolone Acetonide from the clinical outcome data of three randomised trials (NCT01487161, NCT02116972, NCT02357459; n=324) presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 22 May 2017 The findings of a new health economics analysis (n=324) from NCT01487161, NCT02116972, NCT02357459 trials will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd International Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top